Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-9.35m |
Free Cash Flow (TTM) Free Cash Flow | $-9.10m |
Cash position | $5.40m |
EPS (TTM) EPS | $-4.07 |
Short interest | 11.48% |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Sep '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.15 -0.15 |
25%
25%
|
|
EBITDA | -9.20 -9.20 |
18%
18%
|
EBIT (Operating Income) EBIT | -9.35 -9.35 |
18%
18%
|
Net Profit | -13 -13 |
24%
24%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Brian Strem |
Founded | 1998 |
Website | www.kiorapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.